Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists examine immune clues in ovarian cancer

NCT ID NCT07528911

Knowledge-focused Sponsor: Hellenic Cooperative Oncology Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 2 times

Summary

This completed study looked at tumor samples from 687 women with advanced high-grade serous ovarian cancer who were treated with chemotherapy. Researchers examined different types of immune cells in the tumors to see if they were linked to how well patients did. The goal was to better understand the role of the immune system in this type of cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could help doctors better predict how patients with ovarian cancer will respond to standard chemotherapy.
What could go wrong
This is an observational study, not a treatment trial. It only looks at existing tissue samples, so it cannot prove cause and effect or lead directly to a new therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

687 people

The number who actually took part.

Started

Apr 2023

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

-Patients with advanced high grade serous ovarian cancer treated with carboplatin/paclitaxel chemotherapy

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with advanced high grade serous ovarian cancer treated with carboplatin/paclitaxel chemotherapy Exclusion Criteria: * Any other histology than high grade ovarian cancer * Patients with stages I-II (based on FIGO staging)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epithelial high grade serous ovarian cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

malignant ovarian serous tumor ovarian serous adenocarcinoma Tertiary Lymphoid Structures

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Epithelial high grade serous ovarian cancer

Contacts and locations

Locations

  • Hellenic Cooperative Oncology Group

    Athens, Greece